Takaoka Kailey, Cioffi Gino, Waite Kristin A, Finlay Jonathan L, Landi Daniel, Greppin Kaitlyn, Kruchko Carol, Ostrom Quinn T, Barnholtz-Sloan Jill S
Science Research & Engineering Program, Hathaway Brown School, Shaker Heights, Ohio, USA.
Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.
Neurooncol Pract. 2022 Aug 3;10(1):41-49. doi: 10.1093/nop/npac062. eCollection 2023 Feb.
There are limited data available on incidence and survival of patients with choroid plexus tumors (CPT). This study provides the most current epidemiological analysis of choroid plexus tumors from 2004 to 2017 in the United States.
Data on 2013 patients with CPT were acquired from the Central Brain Tumor Registry of the United States in collaboration with the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute, from 2004 to 2017. CPT cases were classified by the following pathological subtypes: choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Frequencies and age-adjusted incidence rates (AAIR) per 100 000 and rate ratios per 100 000 (IRR) were reported for age, sex, race, and ethnicity for each pathological subtype with 95% confidence intervals (95% CI). Using CDC's National Program of Cancer Registries survival database, survival curves and hazard ratios (HRs) evaluated overall survival from 2001 to 2016.
CPP had the highest overall incidence (AAIR: 0.034, 95% CI: 0.033-0.036), followed by CPC (AAIR: 0.008, 95% CI: 0.008-0.009) and aCPP (AAIR: 0.005, 95% CI: 0.005-0.006). Incidence was highest among children less than one year old among all subtypes (CPP AAIR: 0.278; aCPP AAIR: 0.140; CPC AAIR: 0.195), reducing as patients aged. Overall survival was worse among patients with CPC, being five times more likely to die compared to patients with CPP (HR: 5.23, 95% CI: 4.05-7.54, < .001).
This analysis is the most current and comprehensive study in the US on the incidence and survival for CPT. Population based statistics provide critical information in understanding disease characteristics, which impact patient care and prognosis.
关于脉络丛肿瘤（CPT）患者的发病率和生存率的数据有限。本研究提供了2004年至2017年美国脉络丛肿瘤最新的流行病学分析。
2004年至2017年期间，与疾病控制和预防中心（CDC）及国家癌症研究所合作，从美国中央脑肿瘤登记处获取了2013例CPT患者的数据。CPT病例按以下病理亚型分类：脉络丛乳头状瘤（CPP）、非典型脉络丛乳头状瘤（aCPP）和脉络丛癌（CPC）。报告了各病理亚型按年龄、性别、种族和族裔划分的每10万人的频率和年龄调整发病率（AAIR）以及每10万人的率比（IRR），并给出95%置信区间（95%CI）。使用CDC的国家癌症登记项目生存数据库，评估了2001年至2016年的总生存曲线和风险比（HR）。
CPP的总体发病率最高（AAIR：0.034，95%CI：0.033 - 0.036），其次是CPC（AAIR：0.008，95%CI：0.008 - 0.009）和aCPP（AAIR：0.005，95%CI：0.005 - 0.006）。在所有亚型中，一岁以下儿童的发病率最高（CPP的AAIR：0.278；aCPP的AAIR：0.140；CPC的AAIR：0.195），随着患者年龄增长发病率降低。CPC患者的总生存率较差，与CPP患者相比死亡可能性高五倍（HR：5.23，95%CI：4.05 - 7.54，<0.001）。
本分析是美国关于CPT发病率和生存率的最新、最全面的研究。基于人群的统计数据为理解疾病特征提供了关键信息，这些特征会影响患者护理和预后。
